Johnson & Johnson on Tuesday announced a definitive agreement to acquire Alios BioPharma, a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.8 billion in cash.
Respiratory Syncytial Virus appears to cause milder illness than influenza in adults age 50 or older, researchers at Marshfield Clinic Research Foundation announced,
Teva Pharmaceutical Industries will spend up to $165 million to buy a company developing a drug to prevent viral respiratory infections.
An Anglo-Swedish drug maker said it is discontinuing further development of a drug that is designed to prevent a respiratory virus that infects the lungs and breathing passages.
AstraZeneca's biologics unit has received a second complete response letter from the Food and Drug...